The PICO Framework

🟢 Lite — Quick Review (1h–1d)

Rapid summary for last-minute revision before your exam.

Evidence-Based Medicine (EBM) integrates the best available research with clinical expertise and patient values. The exam tests your ability to frame a clinical question using PICO (Patient, Intervention, Comparison, Outcome) and then appraise diagnostic, therapeutic, and prognostic studies. The high-yield formulas are:

PPV = (Sens × Prev) / [(Sens × Prev) + ((1 − Spec) × (1 − Prev))]
NPV = (Spec × (1 − Prev)) / [(Spec × (1 − Prev)) + ((1 − Sens) × Prev)]
LR+ = Sens / (1 − Spec), LR− = (1 − Sens) / Spec
ARR = Risk_treatment − Risk_control, NNT = 1 / ARR

Remember: sensitivity and specificity are fixed test properties; PPV/NPV shift with prevalence. Use NNT, not relative risk reduction, when counselling Saudi primary care patients.

🟡 Standard — Regular Study (2d–2mo)

Standard content for students with a few days to months.

The PICO Framework

A good clinical question has four parts: Patient/problem, Intervention (or exposure), Comparator, Outcome. PICO turns a vague concern (e.g. “does metformin help?”) into a searchable question (e.g. “In adults with type 2 diabetes [P], does metformin [I] compared with lifestyle modification [C] reduce cardiovascular mortality [O]?”). The Saudi GP Board commonly presents long vignettes; identifying the PICO shapes your search strategy and appraisal focus.

Hierarchy of Evidence

From strongest to weakest: systematic reviews/meta-analyses of RCTs → individual RCTs → cohort studies → case-control studies → case series/reports → expert opinion. Within the Saudi MoH Clinical Practice Guideline pathway, recommendations are graded A (RCT-derived) through D (expert consensus). Match study design to the question: therapy → RCT; prognosis → inception cohort; diagnosis → cross-sectional comparison against a gold standard.

Diagnostic Test Appraisal

Validity questions: was the spectrum of patients representative (spectrum bias)? Did every patient receive the gold standard regardless of the index test result (verification bias)? Was the reader blinded? Once valid, compute sensitivity, specificity, and likelihood ratios, then apply them using pre-test probability (in many papers local disease prevalence from Saudi registries). A Fagan nomogram converts pre-test probability to post-test probability once you know the LR.

Therapy and Prognosis Trial Appraisal

Check randomization with allocation concealment, blinding (patient, provider, outcome assessor), intention-to-treat analysis, and loss to follow-up <20%. For prognosis, look for an inception cohort followed long enough for clinically relevant events and reported as a hazard ratio with 95% confidence interval (CI).

Decision Metrics for Practice

ARR and NNT translate trial results into bedside language. If a statin trial reports ARR = 0.02 over 5 years, NNT = 50 for 5 years — a figure that can be shared during informed consent.

🔴 Extended — Deep Study (3mo+)

Comprehensive coverage for students on a longer study timeline.

Edge Cases and Bayesian Reasoning

A common trap is the positive predictive value paradox: at low prevalence, even a test with 95% sensitivity and 95% specificity yields many false positives. In a Saudi primary-care screening scenario such as universal vitamin D screening in young adults (low pre-test probability of severe deficiency), a “positive” result in many papers requires confirmatory testing or a higher LR+ threshold. Always anchor PPV to local prevalence, not textbook figures from Western populations. Screening in the Kingdom’s ministry primary-care centres frequently relies on prevalence-adjusted PPV before initiating referrals.

Common Mistakes to Avoid

Conflating sensitivity with PPV: sensitivity describes diseased patients; PPV describes positive-test patients and depends on prevalence.
Quoting relative risk reduction (RRR) to patients instead of NNT — a 50% RRR can correspond to ARR of 0.5% and NNT of 200, which sounds very different in shared decision-making.
Ignoring the 95% CI of an RR or HR; a result that crosses 1.0 is not statistically significant.
Forgetting to round NNT appropriately — always round up, because NNT must be a whole treated patient.
Using odds ratios as if they were relative risks when the outcome is common (>10%).
Appraising a case-control study to answer a therapy question — wrong design for the wrong PICO.

Practice Prompts

MCQ 1: A new rapid antigen test for streptococcal pharyngitis has sensitivity 85% and specificity 90%. In a clinic where pharyngitis prevalence is 20%, what is the PPV? Solution: PPV = (0.85 × 0.20) / [(0.85 × 0.20) + (0.10 × 0.80)] = 0.17 / 0.25 = 0.68 (68%).

MCQ 2: A hypertension RCT shows event rates of 8% in the active arm and 12% in the placebo arm over 3 years. Compute ARR and NNT. Solution: ARR = 0.12 − 0.08 = 0.04 (4%); NNT = 1 / 0.04 = 25 patients for 3 years to prevent one event.

Content adapted based on your selected roadmap duration. Switch tiers using the selector above.

The PICO Framework